SomaLogic, Inc. announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company. SomaLogic will become the sole provider of high-plex proteomics technology to G42. This initiative spans the United Arab Emirates (UAE) and Kingdom of Saudi Arabia (KSA).

As part of the agreement between the two entities G42 will be the first certified site in the Middle East. The SomaLogic Certified Site program gives labs and institutions—including academia and contract research organizations (CROs)—access to the SomaScan Assay, with more than 7,000 protein measurements per sample and up to 90 samples per assay kit. SOMAmer® reagents have been optimized for specificity with specific binding to target epitopes with coefficients of variation (CVs) of approximately 5%, versus polyclonal antibodies that can result in non-specific binding, with CVs as high as 25%.

SomaLogic recently announced Certified Sites in the U.S., Singapore and Japan. SomaLogic and G42 will collaborate on business development, strategy and applications. G42 will be the sole laboratory partner for SomaLogic's SomaScan® Platform for the life sciences and healthcare markets in the UAE and KSA.

As part of the agreement, G42 Healthcare will establish a lab in Abu Dhabi where it will use the SomaScan Assay kits to run protein measurements on samples from life sciences researchers. Under the agreement, G42 is now a provider of SomaSignal® tests in the region. The tests are currently being used at the Cleveland Clinic Abu Dhabi, provided by Mubadala Health.

G42 Healthcare and Mubadala Health recently partnered to create an integrated healthcare company. The new entity will leverage the strength of this combined network, which includes state-of-the-art healthcare facilities and digital platforms.